Loading clinical trials...
Loading clinical trials...
Robust Armored Dual-Cytokine (IL-15/IL-21) GPC3-CAR T Cells for Atypical Teratoid Rhabdoid Tumors and Central Nervous System Rhabdoid Tumors (RADIANT)
Conditions
Interventions
21.15.GPC3-CAR T Cells
Locations
1
United States
Texas Children's Hospital
Houston, Texas, United States
Start Date
September 1, 2026
Primary Completion Date
October 31, 2029
Completion Date
October 31, 2044
Last Updated
April 7, 2026
NCT05407441
NCT02114229
Lead Sponsor
Baylor College of Medicine
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions